Literature DB >> 10446876

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.

S Amin1, M P LaValley, R W Simms, D T Felson.   

Abstract

OBJECTIVE: To determine if vitamin D is more effective than no therapy or calcium alone in the management of corticosteroid-induced osteoporosis, and to determine how vitamin D compares with other osteoporosis therapies, e.g., bisphosphonates, calcitonin, or fluoride, for this condition.
METHODS: We evaluated all formulations of vitamin D, including its active metabolites and analogs. A systematic search for published and unpublished studies was conducted using MEDLINE (1966-December 1997), bibliographic references, abstracts from proceedings of recent national meetings, and contact with pharmaceutical companies and content experts. We included all randomized controlled trials lasting at least 6 months (and reporting extractable results), of patients receiving oral corticosteroids, that compared vitamin D with either 1) no therapy or calcium alone, or 2) bisphosphonates, calcitonin, or fluoride. The primary outcome measure of interest was change in lumbar spine bone mineral density.
RESULTS: We found a moderate beneficial effect of vitamin D plus calcium versus no therapy or calcium alone (9 trials) (effect size 0.60; 95% confidence interval [95% CI] 0.34, 0.85; P < 0.0001). In comparisons of vitamin D with other osteoporosis therapies, bisphosphonates were more effective than vitamin D (6 trials) (effect size 0.57; 95% CI 0.09, 1.05). Calcitonin was similar in efficacy to vitamin D (4 trials) (effect size 0.03; 95% CI -0.39, 0.45). Fluoride was more effective than vitamin D, but there were only 2 trials.
CONCLUSION: Vitamin D plus calcium is superior to no therapy or calcium alone in the management of corticosteroid-induced osteoporosis. Vitamin D is less effective than some osteoporosis therapies. Therefore, treatment with vitamin D plus calcium, as a minimum, should be recommended to patients receiving long-term corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446876     DOI: 10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

Review 1.  Bone abnormalities in gastrointestinal and hepatic disease.

Authors:  F A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Effects of prematurity, intrauterine growth status, and early dexamethasone treatment on postnatal bone mineralisation.

Authors:  S Kurl; K Heinonen; E Länsimies
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

Review 3.  Glucocorticoid-induced osteoporosis: treatment options and guidelines.

Authors:  Michael Maricic
Journal:  Curr Osteoporos Rep       Date:  2005-03       Impact factor: 5.096

4.  Reporting of systematic reviews of micronutrients and health: a critical appraisal.

Authors:  Mei Chung; Ethan M Balk; Stanley Ip; Gowri Raman; Winifred W Yu; Thomas A Trikalinos; Alice H Lichtenstein; Elizabeth A Yetley; Joseph Lau
Journal:  Am J Clin Nutr       Date:  2009-02-25       Impact factor: 7.045

Review 5.  Review of new guidelines for the management of glucocorticoid induced osteoporosis.

Authors:  Swamy R Venuturupalli; Wendy Sacks
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 6.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

Review 7.  Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

Authors:  Hennie G Raterman; Irene E M Bultink; Willem F Lems
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

Review 8.  Glucocorticoid-induced osteoporosis: who to treat with what agent?

Authors:  René Rizzoli; Emmanuel Biver
Journal:  Nat Rev Rheumatol       Date:  2014-11-11       Impact factor: 20.543

Review 9.  Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.

Authors:  R N J de Nijs; J W G Jacobs; A Algra; W F Lems; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2004-05-07       Impact factor: 4.507

Review 10.  Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol.

Authors:  Johann D Ringe; Erich Schacht
Journal:  Rheumatol Int       Date:  2004-06-30       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.